Remarkably, this naked peptide has a profound effect in reducing the profibrotic TGF-β signaling pathway in cells and in vivo and a modified formulation has been developed for the administration of the peptide in patients with IPF. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.